(Q85810701)

English

The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients

scientific article published on 27 December 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Tally Levy

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Roi Weiser

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Erez Ben Shem

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Abraham Golan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Joseph Menczer

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

27 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

129

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

165-168

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Diagnosis and management of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

The Potential Value of CA125 as a Tumour Marker in Small Volume, Non-Evaluable Epithelial Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Ovarian cancer: markers of response

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.024

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.12.024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274778%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85810701&oldid=1370843264"